Hide metadata

dc.date.accessioned2020-07-06T19:53:02Z
dc.date.available2020-07-06T19:53:02Z
dc.date.created2019-06-12T12:40:22Z
dc.date.issued2019
dc.identifier.citationBogsrud, Martin Prøven Græsdal, Asgeir Johansen, Dan Langslet, Gisle Hovland, Anders Arnesen, Kjell Erik Mundal, Liv Retterstøl, Kjetil Wium, Cecilie Holven, Kirsten Bjørklund . LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a)in a large cohort of predominantly genetically verified familial hypercholesterolemia. Journal of Clinical Lipidology. 2019, 13(2), 279-286
dc.identifier.urihttp://hdl.handle.net/10852/77558
dc.description.abstractCurrent treatment goals for familial hypercholesterolemia (FH) recommended by the European Atherosclerosis Society (EAS) are LDL-C ≤2.5 mmol/L (∼100 mg/dL) or ≤1.8 mmol/L (∼70 mg/dL) in very high-risk subjects. Objective The objective of the present study was to investigate characteristics and treatment status in subjects with genetically verified FH followed at specialized lipid clinics in Norway. Methods Data from treatment registries of 714 adult (>18 years) subjects with FH. Results Fifty-seven percent were female. Mean age (SD) at last visit was 44 (16.3) years, and the subjects had been followed at a lipid clinic for 11.1 (7.9) years. Two hundred forty-five (34%) were classified as very-high-risk, and 44% of these had established coronary heart disease. Very-high-risk FH subjects more often received maximal statin dose (54% vs 33%, P < .001), ezetimibe (76% vs 48%, P < .001) or resins (23% vs 9%, P < .001), and achieved LDL-C was lower (3.2 vs 3.5 mmol/L [124 vs 135 mg/dL], P = .003) than normal-risk FH. LDL-C treatment goal was achieved in 25% and 8% of subjects with normal-risk and very-high-risk FH, respectively. Lp(a) levels were available in 599 subjects, and they were divided into 2 groups: ≥90 mg/dL (n = 96) and <90 mg/dL (n = 503). Despite similar lipid levels, body mass index, smoking status, presence of diabetes, and blood pressure, prevalence of coronary heart disease was doubled in the high- compared to low-Lp(a) group (30% vs 14%, P < .001). Conclusion Very few FH subjects achieve their LDL-C treatment goal. New treatment modalities are needed. Independent of LDL-C and other risk factors, high Lp(a) seem to be an important additional risk factor in genetically verified FH.
dc.languageEN
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleLDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a)in a large cohort of predominantly genetically verified familial hypercholesterolemia
dc.typeJournal article
dc.creator.authorBogsrud, Martin Prøven
dc.creator.authorGræsdal, Asgeir
dc.creator.authorJohansen, Dan
dc.creator.authorLangslet, Gisle
dc.creator.authorHovland, Anders
dc.creator.authorArnesen, Kjell Erik
dc.creator.authorMundal, Liv
dc.creator.authorRetterstøl, Kjetil
dc.creator.authorWium, Cecilie
dc.creator.authorHolven, Kirsten Bjørklund
cristin.unitcode185,51,13,20
cristin.unitnameSeksjon for klinisk ernæring
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1
dc.identifier.cristin1704311
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal of Clinical Lipidology&rft.volume=13&rft.spage=279&rft.date=2019
dc.identifier.jtitleJournal of Clinical Lipidology
dc.identifier.volume13
dc.identifier.issue2
dc.identifier.startpage279
dc.identifier.endpage286
dc.identifier.doihttps://doi.org/10.1016/j.jacl.2019.01.010
dc.identifier.urnURN:NBN:no-80611
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1933-2874
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/77558/1/Til%2BCristin.pdf
dc.type.versionAcceptedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International